Selective Serotonin Reuptake Inhibitor (SSRI) News and Research

RSS
Selective Serotonin Reuptake Inhibitor (SSRI) is a type of drug that is used to treat depression. SSRIs slow the process by which serotonin (a substance that nerves use to send messages to one another) is reused by nerve cells that make it. This increases the amount of serotonin available for stimulating other nerves. Also called selective serotonin reuptake inhibitor.
PET imaging agent may help predict effectiveness of depression treatment

PET imaging agent may help predict effectiveness of depression treatment

SSRI treatment improves cognitive and social functioning in young children with fragile X

SSRI treatment improves cognitive and social functioning in young children with fragile X

Antidepressant initiation more frequent among people with Alzheimer's disease even before diagnosis

Antidepressant initiation more frequent among people with Alzheimer's disease even before diagnosis

Use of antidepressants in late pregnancy may be associated with increased risk of PPHN

Use of antidepressants in late pregnancy may be associated with increased risk of PPHN

Johns Hopkins researchers develop new strategies to treat depression in children, adolescents

Johns Hopkins researchers develop new strategies to treat depression in children, adolescents

Scientists receive NARSAD Distinguished Investigator Grants for mental health research

Scientists receive NARSAD Distinguished Investigator Grants for mental health research

Epidurals and reduced postpartum depression: an interview with Dr. Zakowski

Epidurals and reduced postpartum depression: an interview with Dr. Zakowski

Anti-depressants could slow onset of Alzheimer's disease

Anti-depressants could slow onset of Alzheimer's disease

Anxiety relief in children: an interview with Dr. Golda Ginsburg, Johns Hopkins Children’s Center

Anxiety relief in children: an interview with Dr. Golda Ginsburg, Johns Hopkins Children’s Center

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

Eli Lilly reports edivoxetine Phase III program did not meet primary endpoint for major depressive disorder

Eli Lilly reports edivoxetine Phase III program did not meet primary endpoint for major depressive disorder

Study reveals new findings on role of psychotherapy in regulating serotonin receptors

Study reveals new findings on role of psychotherapy in regulating serotonin receptors

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Alarming report on persistent side effects of antidepressant drugs published online

Alarming report on persistent side effects of antidepressant drugs published online

SSRI antidepressants taken during pregnancy do not impact infant's growth over the first year

SSRI antidepressants taken during pregnancy do not impact infant's growth over the first year

No significant link between SSRI use during pregnancy and risk of stillbirth, neonatal death

No significant link between SSRI use during pregnancy and risk of stillbirth, neonatal death

Hot flashes and night sweats can return after SSRI treatment in women

Hot flashes and night sweats can return after SSRI treatment in women

Paroxetine shows promise against heart failure

Paroxetine shows promise against heart failure

Critically ill patients on antidepressants more likely to die

Critically ill patients on antidepressants more likely to die

Delayed loss of nerve cells in the brain linked to symptoms of depression following stroke

Delayed loss of nerve cells in the brain linked to symptoms of depression following stroke